Liquid Biopsy For Cancer Diagnostics Market 2025

Liquid Biopsy For Cancer Diagnostics Market Definition

Liquid biopsy for cancer diagnostics refers to a minimally invasive technique that enables the detection and monitoring of cancer through the analysis of biomarkers present in body fluids such as blood, urine, or saliva. This diagnostic approach is increasingly transforming cancer care by offering a less invasive alternative to traditional tissue biopsies, which often require surgical procedures. The liquid biopsy for cancer diagnostics market consists of sales, by entities (organizations, sole traders and partnerships) of liquid biopsy for cancer diagnostics products and services that are utilized by healthcare professionals for early cancer detection, tracking disease progression, monitoring treatment efficacy and detecting recurrence. These diagnostic tools are especially advantageous for cases where tissue biopsy is challenging or impossible, such as in advanced-stage cancers or when monitoring for residual disease.

Liquid Biopsy For Cancer Diagnostics Market Segmentation

The liquid biopsy for cancer diagnostics market is segmented by type, by cancer, by sample and by end user. By Type – The liquid biopsy for cancer diagnostics market is segmented by type into: a) Product b) Services The product market was the largest segment of the liquid biopsy for cancer diagnostics market segmented by type, accounting for 72.93% or $6,728.96 million of the total in 2024. Going forward, the services segment is expected to be the fastest growing segment in the liquid biopsy for cancer diagnostics market segmented by type, at a CAGR of 17.90% during 2024-2029. By Cancer – The liquid biopsy for cancer diagnostics market is segmented by cancer into: a) Lung Cancer b) Breast Cancer c) Colon Cancer d) Other Cancers The lung cancer market was the largest segment of the liquid biopsy for cancer diagnostics market segmented by cancer, accounting for 32.67% or $3,014.45 million of the total in 2024. Going forward, the lung cancer segment is expected to be the fastest growing segment in the liquid biopsy for cancer diagnostics market segmented by cancer, at a CAGR of 18.99% during 2024-2029. By Sample – The liquid biopsy for cancer diagnostics market is segmented by sample into: a) Blood b) Urine c) Saliva The blood market was the largest segment of the liquid biopsy for cancer diagnostics market segmented by sample, accounting for 79.82% or $7,365.24 million of the total in 2024. Going forward, the urine segment is expected to be the fastest growing segment in the liquid biopsy for cancer diagnostics market segmented by sample, at a CAGR of 18.84% during 2024-2029. By End User – The liquid biopsy for cancer diagnostics market is segmented by end user into: a) Hospitals b) Diagnostic Centers c) Other End Users The hospitals market was the largest segment of the liquid biopsy for cancer diagnostics market segmented by end user, accounting for 55.83% or $5,151.13 million of the total in 2024. Going forward, the diagnostic centers segment is expected to be the fastest growing segment in the liquid biopsy for cancer diagnostics market segmented by end user, at a CAGR of 19.95% during 2024-2029. By Geography - The liquid biopsy for cancer diagnostics market is segmented by geography into: o Asia Pacific • China • India • Japan • Australia • Indonesia • South Korea o North America • USA • Canada o South America • Brazil o Western Europe • France • Germany • UK • Italy • Spain o Eastern Europe • Russia o Middle East
o Africa North America was the largest region in the liquid biopsy for cancer diagnostics market, accounting for 47.21% or $4,355.95 million of the total in 2024. It was followed by Western Europe, Asia Pacific and then the other regions. Going forward, the fastest-growing regions in the liquid biopsy for cancer diagnostics market will be Asia Pacific and Western Europe where growth will be at CAGRs of 18.06% and 17.14% respectively. These will be followed by North America and South America where the markets are expected to grow at CAGRs of 16.37% and 14.04% respectively.

Liquid Biopsy For Cancer Diagnostics Market Drivers

The key drivers of the liquid biopsy for cancer diagnostics market include: Increasing Cancer Prevalence Increasing cancer prevalence is expected to be a key driver of the growth of the liquid biopsy for cancer diagnostics market in the forecast period. Liquid biopsies provide a non-invasive approach to the early detection of cancer, which is increasingly important as cancer cases continue to rise. By enabling early diagnosis, liquid biopsies facilitate prompt treatment, potentially enhancing patient outcomes and improving overall healthcare efficiency. For instance, in February 2024, according to the World Health Organization, a Switzerland-based intergovernmental organization, by 2050, over 35 million new cancer cases were projected, representing a 77% increase compared to the estimated 20 million cases in 2022. Therefore, increasing cancer prevalence will drive demand for liquid biopsy for cancer diagnostics going forward.

Liquid Biopsy For Cancer Diagnostics Market Restraints

The key restraints on the liquid biopsy for cancer diagnostics market include: Lack of Trained Personnel The lack of trained personnel is expected to limit the growth of the liquid biopsy for the cancer diagnostics market in the forecast period. If the healthcare workforce is not adequately trained, the likelihood of incorrect interpretations of liquid biopsy results rises. This can result in misdiagnoses, unnecessary treatments, or missed opportunities for early cancer detection, potentially damaging patient confidence in the technology and hindering its widespread adoption. For instance, in September 2024, according to Oncology Nursing News, a US-based provider of news and clinical insights for oncology nursing professionals, by 2025, the United States is expected to face a shortage of between 200,000 and 450,000 oncology nurses. Therefore, a lack of trained personnel may hinder the growth of liquid biopsy in the cancer diagnostics market.

Liquid Biopsy For Cancer Diagnostics Market Trends

Major trends shaping the liquid biopsy for cancer diagnostics market include: High-Precision Liquid Biopsy For Identifying Cancer Biomarkers Major companies operating in the liquid biopsy for cancer diagnostics market are focusing on developing high-precision liquid biopsy for identifying cancer biomarkers. High-precision liquid biopsy refers to advanced techniques used to analyze circulating biomarkers in bodily fluids, primarily blood, to detect and monitor cancer with a high degree of accuracy. For instance, in September 2024, Strand Life Sciences, an India-based genomics and bioinformatics software and services provider, launched the somatic advantage 74 Liquid Biopsy (SA74 LB) test. This high-precision liquid biopsy test detects circulating tumor deoxyribonucleic acid (ctDNA) in blood samples from cancer patients, analyzing 74 clinically significant genes to offer valuable insights for treatment decisions. The SA74 LB test is designed to be minimally invasive, requiring only a blood sample, thus providing a more convenient alternative to traditional tissue biopsies. Utilizing Unique Molecular Identifiers (UMIs) ensures high-accuracy detection of genetic variants, enabling clinicians to identify potential biomarkers and optimize treatment strategies effectively. Advancements In Automated Liquid Biopsy Technologies For Oncology And Prenatal Cares Companies operating in the liquid biopsy for cancer diagnostics market are revolutionizing next-generation automated liquid biopsy technologies for oncology and prenatal care. This automation reduces manual handling and increases reproducibility, which is important for clinical diagnostics where precision is critical. For instance, in October 2024, QIAGEN, Germany-based and specializing in sample and assay technologies, announced the expansion of its automated liquid biopsy portfolio, aimed at advancing applications in oncology, prenatal care, and organ transplantation. The enhancements include an upgraded EZ1&2 ccfDNA (circulating cell-free deoxyribonucleic acid) Kit, capable of processing up to 24 samples using 10 mL (milliliter) of serum or plasma, along with the introduction of a new urine protocol. Additionally, the company launched the QIAsymphony DSP Circulating DNA Kits, designed for the fully automated extraction of circulating cell-free DNA (ccfDNA) from larger sample volumes. These innovations are tailored to improve the sensitivity and accuracy of liquid biopsies, particularly for the detection of low-frequency mutations in cancer diagnostics while ensuring compliance with regulatory standards for in vitro diagnostics.

Opportunities And Recommendations In The Liquid Biopsy For Cancer Diagnostics Market

Opportunities – The top opportunities in the liquid biopsy for cancer diagnostics market segmented by type will arise in the product segment, which will gain $7,398.53 million of global annual sales by 2029. The top opportunities in the liquid biopsy for cancer diagnostics market segmented by cancer will arise in the lung cancer segment, which will gain $4,175.64 million of global annual sales by 2029. The top opportunities in the liquid biopsy for cancer diagnostics market segmented by end user will arise in the hospitals segment, which will gain $5,169.11 million of global annual sales by 2029. The top opportunities in the liquid biopsy for cancer diagnostics market segmented by sample will arise in the blood segment, which will gain $8,227.62 million of global annual sales by 2029. The liquid biopsy for cancer diagnostics market size will gain the most in the USA at $4,287.28 million. Recommendations- To take advantage of the opportunities, The Business Research Company recommends the liquid biopsy for cancer diagnostics companies to focus on developing high-precision liquid biopsy solutions, focus on advancing automated liquid biopsy technologies, focus on advancing next-generation tools for enhanced cancer screening, focus on advancing next-generation liquid biopsy solutions, focus on enhancing tumor detection and profiling in liquid biopsy, expand in emerging markets, focus on expanding distribution channels for liquid biopsy solutions, focus on developing competitive and accessible pricing strategies, focus on building awareness through targeted educational campaigns, focus on strengthening digital and social media marketing and focus on targeting hospitals and diagnostic centers for enhanced market penetration.